Skip to main content
spacbrain

Cerevel Therapeutics Holdings

Closed (deSPAC)

Health Care · clinical-stage neuroscience biopharmaceuticals

What it is
Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases
What it’s doing now
Merging with ARYA Sciences Acquisition Corp II (ARYB) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com. Special Note Regarding

Source: DEFM14A, accession 0001193125-24-009698

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "AbbVie agreed to acquire Cerevel for $45 per share" [https://www.rosenlegal.com/cases/cerevel-therapeutics-holdings-inc] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "shares of Cerevel for $45.00 per share in cash" [https://www.newsfilecorp.com/release/210262/Cerevel-Therapeutics-is-Being-Investigated-After-Announcing-a-45-Per-Share-Merger-Offer-from-AbbVie-Contact-BFA-Law-to-Discuss-How-this-Impacts-You] [WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "AbbVie agreed to acquire Cerevel for $45 per share" [https://www.rosenlegal.com/cases/cerevel-therapeutics-holdings-inc] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. shares of Cerevel for $45.00 per share in cash." [https://www.newsfilecorp.com/release/210262/Cerevel-Therapeutics-is-Being-Investigated-After-Announcing-a-45-Per-Share-Merger-Offer-from-AbbVie-Contact-BFA-Law-to-Discuss-How-this-Impacts-You] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On December 6, 2023, Cerevel Therapeutics Holdings, Inc. ("Cerevel") entered into an Agreement and Plan of Merger with AbbVie Inc." [https://www.tradingcalendar.com/post/cerevel-abbie-abbv-cere-merger]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Cerevel Therapeutics Holdings is merging with ARYA Sciences Acquisition Corp II (ARYB) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $320M · unsourced

Structure per SEC accession(s) 0001193125-20-212601, 0001193125-24-009698. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Cerevel Therapeutics Holdings going public?

Cerevel Therapeutics Holdings has an approved merger with the SPAC ARYA Sciences Acquisition Corp II (ARYB). Deal status: Closed (deSPAC).

Does Cerevel Therapeutics Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals